Next Frontier Pharmaceuticals

Next Frontier Pharmaceuticals is a biotechnology company specializing in the development and manufacturing of cannabinoid and psychedelic-based therapies. The company's flagship product is SYNDROS (dronabinol oral solution), an FDA-approved treatment for chemotherapy-induced nausea and vomiting and AIDS-related anorexia. Through its subsidiary, Benuvia Manufacturing, the company operates a large-scale, DEA-permitted facility in Round Rock, Texas, which produces high-purity synthetic APIs for internal use and contract manufacturing. Next Frontier's pipeline includes several investigational programs targeting dermatological conditions such as psoriasis and eczema, as well as a growing portfolio of psychedelic compounds including MDMA and psilocybin. The company was acquired by Jupiter Wellness in 2022, positioning it as a leader in the pharmaceutical cannabinoid and psychedelic sectors.